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Abstract Despite advancements in treatments for acute
coronary syndromes over the last 10 years, they continue to
be life-threatening disorders. Currently, the standard of
treatment includes dual antiplatelet therapy consisting of
aspirin plus a P2Y12 receptor antagonist. The thienopy-
ridine class of P2Y12 receptor antagonists, clopidogrel and
prasugrel, have demonstrated efficacy. However, their use
is associated with several limitations, including the need
for metabolic activation and irreversible P2Y12 receptor
binding causing prolonged recovery of platelet function. In
addition, response to clopidogrel is variable and efficacy is
reduced in patients with certain genotypes. Although pra-
sugrel is a more consistent inhibitor of platelet aggregation
than clopidogrel, it is associated with an increased risk of
life-threatening and fatal bleeding. Ticagrelor is an oral
antiplatelet agent of the cyclopentyltriazolopyrimidine
class and also acts through the P2Y12 receptor. In contrast
to clopidogrel and prasugrel, ticagrelor does not require
metabolic activation and binds rapidly and reversibly to the
P2Y12 receptor. In light of new data, this review provides
an update on the pharmacokinetic, pharmacodynamic and
pharmacogenetic profiles of ticagrelor in different study
populations. Recent studies report that no dose adjustment
for ticagrelor is required on the basis of age, gender, eth-
nicity, severe renal impairment or mild hepatic impairment.
The non-P2Y12 actions of ticagrelor are reviewed, showing
indirect positive effects on cellular adenosine concentration
and biological activity, by inhibition of equilibrative
nucleoside transporter-1 independently of the P2Y12
receptor. CYP2C19 and ABCB1 genotypes do not appear
to influence ticagrelor pharmacodynamics. A summary of
drug interactions is also presented.
Key Points
Dual antiplatelet therapy with aspirin and a P2Y12
receptor inhibitor represents the standard of care
treatment for the management of patients with acute
coronary syndrome.
Ticagrelor is the first of a new class of P2Y12
receptor inhibitors, which is distinct from
clopidogrel and prasugrel with respect to its unique
mode of action.
This article provides a comprehensive overview of
the pharmacokinetic, pharmacodynamic and
pharmacogenetic profiles of ticagrelor in different
study populations—updating a previous review on
this topic.
1 Introduction
Acute coronary syndromes (ACS) encompass a spectrum
of unstable coronary artery disease (CAD), involving an
abrupt reduction in coronary blood flow leading to
myocardial ischaemia and/or myocardial infarction (MI)
with or without ST-segment elevation [1]. Associated with
significant morbidity and mortality [2], the pathophysiol-
ogy of the majority of these life-threatening conditions
involves the rupture of an atherosclerotic plaque within a
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coronary artery and subsequent platelet activation, aggre-
gation and thrombus formation [3]. Myocardial injury can
also occur through increased oxygen demand (e.g. stenosis)
or via non-atherothrombotic coronary obstruction (e.g.
arteriospasm) [4]. If untreated, decreased blood flow and
decreased perfusion of the myocardium can lead to
myocardial necrosis [2]. Dual antiplatelet therapy repre-
sents the cornerstone of treatment for ACS. Guidelines
recommend aspirin plus a P2Y12 receptor antagonist, with
selection of the P2Y12 inhibitor dependent on individual
patient characteristics, such as advanced age, and con-
comitant use of immunosuppressant agents [1, 5–7]. The
two classes of P2Y12 receptor antagonist currently avail-
able for antiplatelet therapy are thienopyridines (clopido-
grel and prasugrel) and, more recently, the
cyclopentyltriazolopyrimidines (ticagrelor). Although
widely available in generic form, and previously consid-
ered standard therapy for ACS [8], clopidogrel is associ-
ated with a number of limitations, including a delayed
onset of action due to the need for metabolic activation,
prolonged recovery of platelet function due to irreversible
P2Y12 platelet binding, and variable and reduced anti-
platelet effects in patients with certain genotypes, which
may be related to genetic variations in the enzymes
responsible for clopidogrel metabolic activation [9–11].
Like clopidogrel, prasugrel requires metabolic activation
for antiplatelet activity and binds irreversibly [12]. The
antiplatelet response to prasugrel appears to be more potent
and consistent compared with the response to clopidogrel.
However, as shown in TRITON-TIMI 38 (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel–Thrombolysis in
Myocardial Infarction 38), these positive effects are
accompanied by an increase in the rate of major bleeding
[13].
The P2Y12 receptor antagonist ticagrelor has a unique
mode of action [14]. Ticagrelor does not require metabolic
activation for antiplatelet activity and binds reversibly to
the P2Y12 receptor. In the PLATO (Platelet Inhibition and
Patient Outcomes) study, ticagrelor significantly reduced
the incidence of the composite end point of cardiovascular
death, MI or stroke in patients with ACS, compared with
clopidogrel [15]. There were no significant differences in
overall major bleeding rates between treatments, although
a significantly higher rate of major bleeding not related to
coronary artery bypass grafting (CABG) was seen with
ticagrelor versus clopidogrel [15]. The prospective
PEGASUS-TIMI 54 study showed that long-term therapy
with ticagrelor and low-dose aspirin in patients with a prior
MI ([12 months previously) significantly reduced the
incidence of the primary efficacy end point (a composite of
cardiovascular death, MI or stroke), with an increase in
major bleeding versus placebo [16].
Assessing the pharmacological profile of oral anti-
platelet agents is critical for the appropriate selection of an
antiplatelet agent and/or regimen, particularly given the
broad patient population with ACS, with the potential
range of comorbidities [6, 7]. This article provides a
comprehensive summary of the pharmacokinetic, pharma-
codynamic and pharmacogenetic profiles of ticagrelor,
updating an earlier review on this topic [17].
2 Ticagrelor Pharmacokinetic Profile
2.1 Absorption, Distribution, Metabolism
and Excretion
The pharmacokinetic profile of ticagrelor has been evalu-
ated in healthy volunteers and in patients with CAD,
atherosclerosis and ACS. A regional absorption study in
healthy volunteers showed that the proportion of ticagrelor
that was absorbed decreased the further down the gas-
trointestinal tract that the dose was released [18]. In healthy
volunteers, single oral doses of ticagrelor 0.1–400 mg were
rapidly absorbed, with a median time to reach the maximum
plasma concentration (tmax) of approximately 1.3–2 h.
Similarly, the median tmax for AR-C124910XX (the active
metabolite of ticagrelor) was 1.5–3 h [19, 20]. Alternative
methods of administration have been shown to increase the
rate of absorption of ticagrelor. In healthy volunteers,
administration of ticagrelor as a crushed tablet (dosed orally
or via a nasogastric tube) increased plasma concentrations
of ticagrelor and AR-C124910XX at early time points (0.5
and 1 h post-dose) relative to oral administration of a whole
tablet. The ticagrelor tmax was shorter following crushed
versus whole tablet administration (1 vs 2 h) (Fig. 1) [21].
Further studies are warranted to assess whether adminis-
tration of crushed tablets provides a pharmacodynamic or
clinical benefit in scenarios in which the absorption of
ticagrelor occurs less rapidly than predicted, e.g. in patients
with ACS, in whom tmax values of 3 and 4 h have been
reported for ticagrelor and AR-C124910XX, respectively,
following a 180 mg loading dose [22].
The mean absolute bioavailability of ticagrelor in heal-
thy volunteers is 36 % [18]. Mean and maximum plasma
concentration (Cmax) values of ticagrelor and AR-
C124910XX increase linearly and predictably in a dose-
dependent manner and are stable at steady state in healthy
volunteers [23] and in patients with atherosclerosis [24],
CAD [25] and ACS [22]. The effect of food on exposure to
ticagrelor and AR-C124910XX is small and considered to
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be of minimal clinical significance. Therefore, ticagrelor
can be administered with or without food [26].
In vitro studies evaluating the metabolism of ticagrelor
have been conducted in hepatocyte and microsomal
preparations from several animal species [27]. Multiple
metabolites were identified and the major metabolites
across all species were AR-C124910XX and AR-
C133913XX. Cytochrome P450 (CYP) 3A4 and CYP3A5
were primarily responsible for the formation of AR-
C124910XX, whereas the formation of AR-C133913XX
most likely occurred via CYP3A4, with a lesser contribu-
tion from CYP3A5 [28]. Consequently, potential interac-
tions between ticagrelor and inducers or inhibitors of
CYP3A4 were evaluated in clinical pharmacology studies
and are discussed in greater detail in the ‘Drug Interac-
tions’ section.
Experiments conducted with radiolabelled ticagrelor in
six healthy male volunteers identified ten discrete
metabolites, with unchanged ticagrelor and AR-
C124910XX being the predominant entities observed in the
plasma. AR-C124910XX is present at approximately
30–40 % of the concentration of the parent compound [20,
24]. Following administration of [14C]-ticagrelor, 58 %
was recovered in the faeces and 27 % in the urine; the
levels of unchanged ticagrelor and AR-C124910XX in the
urine were \0.05 % [20]. These data indicate that tica-
grelor is mainly excreted in the faeces, with renal excretion
playing only a minor role; the primary route of excretion
for the active metabolite is most likely biliary secretion.
The mean elimination half-life of ticagrelor is
7.7–13.1 h, whereas the mean elimination half-life of AR-
C124910XX is 7.5–12.4 h [19]. Table 1 summarizes the
key pharmacokinetic parameters of ticagrelor alongside
clopidogrel and prasugrel.
2.2 Ticagrelor Pharmacokinetics in Special
Populations
In 40 healthy volunteers who received ticagrelor 200 mg,
systemic exposure to ticagrelor and AR-C124910XX was
approximately 40–60 % higher in elderly versus young
subjects and in women versus men. However, no dose
adjustment is considered necessary on the basis of either
age or gender [32]; nor is dose adjustment required in
patients with severe renal impairment [33] or mild hepatic
impairment [34]. The use of ticagrelor is contraindicated in
patients with severe hepatic impairment [29]. As ticagrelor
metabolism occurs in the liver [27, 28], exposure to the
parent drug will probably increase in severe hepatic
impairment [29]. In addition, the bleeding risk is increased
in severe hepatic impairment because of reduced synthesis
of coagulation proteins [29]. No pharmacokinetic data are
available in patients with moderate hepatic impairment
(need to consider the risk–benefit of ticagrelor due to
Fig. 1 Arithmetic mean ± standard deviation plasma concentrations
of ticagrelor over time following administration of a 90 mg dose of
ticagrelor administered either orally as a whole tablet, orally as a
crushed tablet or as a crushed tablet via a nasogastric (NG) tube [21].
Compared with a whole tablet: p\ 0.0001 for crushed tablet (NG
tube) at 0.5 and 1 h post-dosing and for crushed tablet at 0.5 h post-
dosing; p\ 0.02 for crushed tablet at 1 h post-dosing (linear mixed-
effects model with sequence, period and treatment as fixed effects,
and volunteer nested within sequence as a random effect). (From:
Teng et al. [21]. With kind permission from Dustri-Verlag)
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probable increase in exposure [29]) or patients receiving
renal dialysis.
In PLATO, the incidence of dyspnoea was higher with
ticagrelor compared with clopidogrel [15, 29]. Ticagrelor
inhibits platelet activity via P2Y12 receptor inhibition and
also via adenosine [35]. A potential mechanism of tica-
grelor-induced dyspnoea involves increased endogenous
levels of adenosine [36]. Adenosine can induce dyspnoea
in normal [37] and asthmatic [38] subjects. Thus, two
randomized, double-blind, placebo-controlled, two-way
crossover studies were conducted to evaluate the pharma-
cokinetics, pharmacodynamics and safety of ticagrelor in
subjects at risk of respiratory impairment (healthy elderly)
and in patients with respiratory impairment (mild asthma or
mild to moderate chronic obstructive pulmonary disease
[COPD]) [39]. Although exposure to ticagrelor (at steady
state) and AR-C124910XX (after a single dose of ticagrelor
and at steady state) appeared to be lower in patients with
asthma or COPD compared with healthy elderly volun-
teers, no consistent relationship was observed between
exposure and minute ventilation, respiratory rate, tidal
volume, spirometry, pulse oximetry or dyspnoea. Further-
more, ticagrelor did not appear to alter pulmonary function
at rest or during exercise; bronchospasm (as determined by
spirometry and pulse oximetry) was not observed in any
cohort [39]. Additionally, diabetic status appears to have
no significant effect on ticagrelor pharmacokinetics (As-
traZeneca, data on file) [40].
The pharmacokinetics of ticagrelor have also been asses-
sed in several different ethnic groups. Ticagrelor and AR-
C124910XX exhibited linear and predictable pharmacoki-
netics in healthy Chinese volunteers at doses of 90 and
180 mg [41]. Exposures to ticagrelor and AR-C124910XX at
steady state were slightly higher in Chinese volunteers com-
pared with Caucasian volunteers in other studies [19, 20]. The
pharmacokinetics of ticagrelor and AR-C124910XX in
Japanese volunteers were assessed in two ethnicity-bridging
studies. Pharmacokinetic profiles were broadly comparable
between Japanese and Caucasian volunteers following single
ascending doses (50–600 mg) and multiple ascending doses
(100 or 300 mg) of ticagrelor [42]. After adjustments to
account for differences in body weight between the ethnic
groups, exposure to ticagrelor and AR-C124910XX was
approximately 20 % greater in Japanese versus Caucasian
participants [42]. These findings were consistent with obser-
vations in a similar study of Japanese patients with CAD [43].
In DISPERSE (Dose Confirmation Study Assessing Anti-
Platelet Effects of AZD6140 vs Clopidogrel in Non-ST-seg-
ment Elevation Myocardial Infarction), after treatment with
ticagrelor (45 or 90 mg twice daily) for 28 days, the area
under the plasma concentration–time curve (AUCs) and Cmax
of ticagrelor and AR-C124910XX were 1.3- to 1.5-fold
greater in Japanese patients than in Caucasian patients
(Fig. 2) [24, 43]. The observed differences in exposure to
ticagrelor in Chinese and Japanese versus Caucasian patients
are not of sufficient magnitude to warrant dose adjustment on
the basis of ethnicity.
Two randomized, open-label, crossover studies evalu-
ated the pharmacokinetic parameters of ticagrelor in His-
panic and African-American patients with CAD [44, 45].
Ticagrelor and AR-C124910XX exhibited similar exposure
in Hispanic and African-American patients compared with
those previously reported in Caucasian patients [25, 44,
45].
Table 1 Summary of key pharmacokinetic and pharmacodynamic parameters of P2Y12 receptor inhibitors
End point Ticagrelor [19, 20, 29] Clopidogrel [29, 30] Prasugrel [31]
Metabolic activation required No
Major metabolite (AR-C124910XX) is
equipotent to the parent compound
Yes Yes
Reversibility of binding to ADP receptor Reversible Irreversible Irreversible
Single-dose pharmacokinetic parameters
tmax Ticagrelor: 1.3–2 h
AR-C124910X: 1.3–3 h
30–60 mina 30 mina
t Ticagrelor: 7.7–13.1 h
AR-C124910X: 7.5–12.4 h
30 mina 7 (2–15) ha
Onset of IPA
40–50 % IPA 30 min 2–4 h 1 h
Maximum IPA 2 h 8 h 3 h
Duration of IPA 3–5 days 7–10 days 5–10 days
ADP adenosine 50-diphosphate, IPA inhibition of platelet aggregation, t elimination half-life, tmax time to reach maximum plasma concentration
a Data are for the active metabolite
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2.3 Drug Interactions
In vitro experiments using human liver microsomes indi-
cate that ticagrelor and AR-C124910XX are predominantly
metabolized by CYP3A4 and, less so, by CYP3A5
enzymes [20, 28]. Metabolism studies demonstrate that, in
addition to being a CYP3A substrate, ticagrelor is a weak
inhibitor or activator of CYP3A [28]. Ticagrelor and AR-
C124910XX appear to have low or no potential to induce
CYP1A1, CYP1A2, CYP2C9, CYP2B6 and CYP3A4, and
no propensity to inhibit CYP1A2, CYP2B6, CYP2C8,
CYP2C19, CYP2D6 and CYP2E1. Unpublished in vitro
studies also indicate that ticagrelor is a substrate and
inhibitor of P-glycoprotein (P-gp) [29].
2.3.1 Effects of Ticagrelor on the Pharmacokinetics
of Other Products
The interaction of ticagrelor and the probe CYP3A sub-
strate midazolam was evaluated in healthy volunteers in
two clinical pharmacology studies [46] and confirmed
earlier unpublished in vitro findings that ticagrelor is a
weak inhibitor of CYP3A. Thus, co-administration of
ticagrelor with CYP3A substrates that have a narrow
therapeutic profile (e.g. ergot alkaloids, cisapride) should
be avoided [29]. Statin compounds are also substrates of
CYP3A and concomitant administration with antiplatelet
agents is common in patients with ACS (90 % of patients
receiving ticagrelor in the PLATO study received con-
comitant statins with no safety concerns) [15]. Two sepa-
rate crossover studies evaluated the interaction between
ticagrelor (loading dose 270 mg; 180 mg twice daily,
7 days) and atorvastatin (80 mg) or simvastatin (80 mg)
[47]. Co-administration with ticagrelor increased the ator-
vastatin Cmax by 23 % and AUC by 36 %. These increases
in Cmax were modest and considered not to be clinically
significant. However, the magnitude of the interaction
between ticagrelor and simvastatin was greater. The mean
simvastatin Cmax and AUC increased by 81 and 56 %,
respectively, in the presence of ticagrelor and, in some
individuals, 2- to 3-fold increases in the simvastatin AUC
were observed. Although the dose of ticagrelor used in
these studies was greater than the clinically approved
regimen, it is recommended that the concomitant use of
simvastatin or lovastatin at doses greater than 40 mg
should be avoided with ticagrelor, as patients may be at
increased risk of statin-related adverse effects [29, 47].
CYP isoenzymes, including 3A4, also play a role in the
oxidative metabolism of ethinyl oestradiol and the
hydroxylation of levonorgestrel. As it is common for
combinations of these compounds to be used in widely
dispensed oral contraceptives, potential interactions with
ticagrelor were assessed in young, healthy women (mean
[standard deviation] age 32.7 [7.1] years) [48]. Co-ad-
ministration of ticagrelor had no significant effects on the
pharmacokinetics of ethinyl oestradiol or levonorgestrel;
thus, no clinically relevant effect of ticagrelor on oral
contraceptive efficacy or safety is expected [48].
One of the most abundant hepatic CYP enzymes
involved in the absorption, distribution, metabolism and
excretion of ticagrelor is CYP2C9. No interaction between
ticagrelor and the model CYP2C9 substrate tolbutamide
was observed in healthy volunteers [49]. Thus, ticagrelor is
unlikely to affect CYP2C9-mediated metabolism of other
drugs and vice versa. As such, a recent European Society of
Cardiology expert position paper concluded that proton
pump inhibitors (which are predominantly metabolized by
CYP2C enzymes) are unlikely to have any significant
pharmacokinetic interaction with ticagrelor [50]. Similarly,
ticagrelor is not expected to affect CYP2D6-mediated drug
metabolism to a clinically relevant extent. In healthy vol-
unteers, co-administration of ticagrelor with the CYP2D6
Fig. 2 Scatter plot of ticagrelor
plasma concentration vs final-
extent inhibition of platelet
aggregation (IPA) in Japanese
patients with stable coronary
artery disease. The prediction
curve shown in the figure is
based on a sigmoid maximum
effect (Emax) model [43]. (From:
Hiasa et al. [43]. With kind
permission from Springer
Science and Business Media)
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substrate venlafaxine resulted in only a small (22 %)
increase in the venlafaxine Cmax and no significant increase
in the venlafaxine AUC [51].
In addition to the CYP enzymes, various transporter
proteins also play a role in the absorption, distribution,
metabolism and excretion of drugs. As suggested by
unpublished in vitro studies, ticagrelor is a weak inhibitor of
P-gp. Concomitant use of ticagrelor and digoxin increased
exposure to digoxin (Cmax by 75 %, AUC by 28 %) [52].
Therefore, appropriate clinical and/or laboratory monitor-
ing is recommended when ticagrelor is administered with
P-gp-dependent drugs possessing a narrow therapeutic
profile (e.g. digoxin).
2.3.2 Effects of Other Products on the Pharmacokinetics
of Ticagrelor
Ticagrelor is a substrate of CYP3A and the use of tica-
grelor with strong CYP3A4 inhibitors or potent CYP3A
inducers was thus an exclusion criterion in the PLATO
study [15]. Concomitant administration of strong CYP3A
inducers (e.g. rifampicin) decreases exposure to ticagrelor.
For example, co-administration of ticagrelor and rifampicin
significantly reduced the Cmax, AUC and plasma half-life
of ticagrelor by 73, 86 and 67 %, respectively [53]. Con-
versely, strong CYP3A4 inhibitors (e.g. ketoconazole,
ritonavir) or moderate CYP3A4 inhibitors (e.g. diltiazem,
fluconazole, grapefruit juice) increase exposure to tica-
grelor. For example, in healthy volunteers, grapefruit juice
increased the ticagrelor Cmax and AUC by 165 and 221 %,
respectively [54]. Moreover, co-administration of keto-
conazole increased the ticagrelor Cmax and AUC by 135
and 632 %, respectively [55]. On the basis of these find-
ings, the use of ticagrelor with strong CYP3A4 inhibitors is
contraindicated [29, 55].
Cyclosporine is a weak inhibitor of CYP3A4, as well as a
potent inhibitor of P-gp. As it is possible that ticagrelor (a
CYP3A4 and P-gp substrate) might be co-administered with
cyclosporine in patientswithACS and comorbidities requiring
immunosuppressive treatment, a crossover study was per-
formed in healthy volunteers to evaluate potential interactions.
Co-administration of ticagrelor with cyclosporine increased
the ticagrelor AUC and Cmax by 283 and 230 %, respectively,
while the pharmacokinetic profile of cyclosporine was unaf-
fected. However, the magnitude of cyclosporine’s effect on
ticagrelor pharmacokinetics was not considered sufficient to
warrant dose adjustment of ticagrelor [56].
The interaction of ticagrelor with two anticoagulants,
heparin and enoxaparin, was evaluated in two studies of
healthy volunteers, and no notable changes in the phar-
macokinetics of ticagrelor or AR-C124910XX were
reported [57]. Furthermore, switching from clopidogrel to
ticagrelor did not substantially affect the pharmacokinetic
profile of ticagrelor [25].
A summary of known ticagrelor drug interactions is
provided in Table 2.
2.3.3 Clinical Outcomes in PLATO in Patient Subgroups
Taking Co-administered Drugs
The majority of ACS patients in the PLATO study were
taking a range of co-administered drugs typical of this
patient population [15]. In predefined subgroups, ticagrelor
significantly reduced the incidence of the primary end point
(a composite of cardiovascular death, MI or stroke) com-
pared with clopidogrel in patients taking lipid-lowering
drugs, beta-blockers, angiotensin-converting enzyme inhi-
bitors and calcium channel blockers. The incidence of the
primary end point was also lower (not significant) with
ticagrelor versus clopidogrel in patients taking angiotensin
II receptor blockers or proton pump inhibitors. PLATO
also demonstrated that ticagrelor was associated with better
clinical outcomes versus clopidogrel in patients on low-
dose maintenance aspirin [58]. Consequently, aspirin doses
\100 mg/day are recommended with ticagrelor [29].
3 Ticagrelor Pharmacodynamic Profile
Table 1 summarizes the key pharmacodynamic parameters
of ticagrelor alongside clopidogrel and prasugrel.
3.1 Mechanism of Action
3.1.1 P2Y12 Receptor Binding
Ticagrelor binds to P2Y12 receptors in a potent and
reversible manner using a binding site distinct from the
adenosine 50-diphosphate (ADP)-binding site [14]. Con-
sequently, binding does not cause an ADP-induced con-
formational change in the P2Y12 receptor, G proteins are
not activated, the receptor remains inactive and ADP
signalling is inhibited [59]. Ticagrelor binds only to the
P2Y12 receptor and not to other P2Y receptor types [60].
Unlike clopidogrel and prasugrel, ticagrelor does not
require metabolic activation and its active metabolite, AR-
C124910XX, is approximately equipotent to ticagrelor at
the P2Y12 receptor. AR-C124910XX is also thought to
contribute to the antiplatelet effect reported with ticagrelor
administration [20].
Reticulated platelets are large, young, newly formed
platelets and have been shown to exhibit increased reac-
tivity, compared with non-reticulated platelets [61]. Plate-
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ticagrelor (40 mg/kg) or clopidogrel (200 mg/kg). Tica-
grelor reduced thrombus formation more effectively com-
pared with clopidogrel [62]. The study reported that a
subpopulation of juvenile platelets, which formed at later
time points, promoted thrombus formation after clopido-
grel but not after ticagrelor. This suggests that, at least in
rats, the recovery of platelet function after treatment with
ticagrelor differs mechanistically from that after treatment
with clopidogrel.
The efficacy of antiplatelet therapy must be balanced
with the risk of bleeding in situations such as planned or
emergency surgery. The vasopressin desmopressin is often
used as a first-line therapy for individuals with bleeding
disorders. The effect of desmopressin on bleeding time in
healthy volunteers receiving ticagrelor was tested in a
randomized, double-blind, two-way crossover study [63].
Healthy volunteers received ticagrelor (270 mg loading
dose; 180 mg twice daily) for 5 days; at day 5, desmo-
pressin (0.3 mcg/kg) or saline intravenous infusions were
then administered. The study reported no significant effect
of desmopressin on bleeding time or inhibition of platelet
aggregation (IPA). However, primary haemostatic activity
was increased [63]. To date, no pharmacological agent has
been shown to reverse the antiplatelet effect of ticagrelor.
Currently, a specific antidote to ticagrelor is under devel-
opment [64]. This antidote, MEDI2452, is a highly specific
neutralizing fragment antigen binding (Fab) and reversed
the antiplatelet activity of ticagrelor in vitro (in human
platelet-rich plasma) and in vivo (in a mouse model of
acute surgery) [64]. MEDI2452 requires further investiga-
tion to assess its potential role in reversal of the antiplatelet
effects of ticagrelor in humans.
Platelet-rich plasma may reverse the antiplatelet effects
of clopidogrel [65], although a more recent study demon-
strated that autologous platelet transfusion did not reverse
the effects of clopidogrel 24 h after the final dose [66]. A
study of the effect of autologous platelet transfusion in
healthy volunteers treated with ticagrelor was recently
completed (ClinicalTrials.gov study ID: NCT01744288)
and the results are to be published.
3.1.2 Effects of Ticagrelor on Adenosine
The clinical characteristics of ticagrelor may be related to
its effect not only through the P2Y12 receptor but also
through adenosine-mediated action [35]. Using an in vitro
model with recombinant Madin–Darby canine kidney cells,
at concentrations of clinical relevance, ticagrelor—and, to
a lesser extent, its metabolites—inhibited cellular adeno-
sine uptake in cells expressing equilibrative nucleoside
transporter-1 (ENT-1) [67]. In the same study, the active
metabolites of clopidogrel and prasugrel did not display
any significant inhibition of ENT-1. This finding was
supported by a clinical study examining coronary blood
flow velocity (CBFV) in healthy men receiving ticagrelor
or placebo, which showed that ticagrelor enhanced ade-
nosine-induced CBFV and the sensation of dyspnoea [68].
The inhibition of ENT-1 by ticagrelor has been reported
from other studies and has been recently reviewed [69].
ENT-1 inhibition protects adenosine from intracellular
metabolism, thereby increasing its concentration and bio-
logical activity, providing potential benefit for the heart in
ischaemia–reperfusion injury [69].
3.1.3 Other Pleiotropic Effects of Ticagrelor
In addition to the ENT-1-mediated effects of ticagrelor, a
comparison of the effect of clopidogrel and ticagrelor on
myocardial infarct size in rats showed that ticagrelor, but
not clopidogrel, reduces myocardial infarct size [70]. The
effect of ticagrelor was dependent on adenosine-receptor
activation with downstream upregulation of endothelial
nitric oxide synthase and cyclooxygenase-2 activity. An
in vitro investigation of the effects of ticagrelor and the
clopidogrel-active metabolite showed that ticagrelor has an
anticoagulant and anti-inflammatory profile and enhances
endothelial nitric oxide synthase activation [71]. These
effects appeared to be mediated independently of P2Y12 or
adenosine receptors.
3.2 Inhibition of Platelet Activity: Data
from Clinical Studies
3.2.1 Healthy Volunteer Studies
Ticagrelor inhibited ADP-induced platelet aggregation in a
dose-dependent manner in healthy volunteers receiving
single 30–400 mg doses, with doses less than 30 mg hav-
ing no significant inhibitory effect [19]. When given twice
daily (50–300 mg), ticagrelor provides a consistently
greater IPA than an equivalent single daily dose
(100–600 mg) [23]. In the study of single and multiple
ascending doses of ticagrelor in Japanese and Caucasian
healthy volunteers, a slightly greater exposure in Japanese
versus Caucasian groups was reported, although pharma-
codynamic responses in terms of IPA and bleeding time
were similar between groups [42].
3.2.2 Patients with Coronary Artery Disease
In Japanese and non-Japanese Asian patients with stable
CAD receiving ticagrelor (45 or 90 mg twice daily) or
clopidogrel (75 mg once daily), IPA was dose dependent
and was greater with ticagrelor versus clopidogrel. In a
subset of Japanese patients, exposure to ticagrelor and its
active metabolite, AR-C124910XX, increased dose
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proportionally (Fig. 3) [43]. Further comparator studies of
ticagrelor versus clopidogrel in Hispanic and African-
American patients reported similar results [44, 45]. Clinical
trials report poorer outcomes for diabetic patients with
ACS compared with patients without diabetes [72]. The
presence of diabetes does not appear to influence response
to ticagrelor. Consistent with the full study population
analysis reported above, subgroup analyses in Hispanic
(AstraZeneca, data on file) and African-American [40]
patients with diabetes also reported greater IPA with tica-
grelor versus clopidogrel.
In patients with stable atherosclerosis, greater IPA was
observed for ticagrelor compared with clopidogrel [24].
Higher doses of ticagrelor (100 and 200 mg twice daily,
and 400 mg once daily) provided more effective IPA than
ticagrelor 50 mg twice daily or clopidogrel 75 mg once
daily at 2 h after initial dosing and at steady state. Fur-
thermore, 4 h post-dosing at steady state, the greater IPA
observed with the higher doses of ticagrelor compared with
ticagrelor 50 mg twice daily or clopidogrel 75 mg was
maintained [24].
3.2.3 Patients with Acute Coronary Syndromes
The PLATO study, a multicentre, double-blind, random-
ized trial of ticagrelor (180 mg loading dose, 90 mg twice
daily thereafter) versus clopidogrel (75 mg once daily), in
patients with ACS, reported no significant differences in
overall major bleeding events (PLATO- and TIMI-defined
bleeding), or fatal or life-threatening bleeding, or rates of
CABG-related major bleeding, or bleeding requiring a
transfusion between treatment groups [15]. Compared with
clopidogrel, rates of non-CABG-related major bleeding
and fatal intracranial bleeding were higher with ticagrelor.
For other types of fatal bleeding, rates were lower with
ticagrelor versus clopidogrel. In the subgroup of ACS
patients in PLATO who were undergoing CABG and who
stopped taking antiplatelet therapy B1 to[6 days prior to
surgery, there was no difference in CABG-related major
bleeding between ticagrelor and clopidogrel [73]. The
ticagrelor prescribing information [29] and current guide-
lines [1, 5–7] recommend that ticagrelor is discontinued at
least 24 h before urgent CABG [1, 5] and 3–5 days [7] or
at least 5 days [1, 5, 6, 29] prior to planned CABG.
A substudy of the PLATO trial showed greater IPA with
ticagrelor versus clopidogrel, with separation of profiles
reported within the first hours of treatment and also during
maintenance therapy [74]. Consistent with the results of the
PLATO study, in the DISPERSE-2 study of ticagrelor
versus clopidogrel in patients with non-ST-segment ele-
vation ACS, there was no difference between groups in
major bleeding rates [75]. Although not significant, a trend
for a reduction in MI rates was seen for ticagrelor versus
clopidogrel in the DISPERSE-2 substudy. In a further
study of 50 patients with ST-segment elevation MI
(STEMI), ticagrelor and prasugrel effects on platelet
reactivity were not significantly different [76]. Interest-
ingly, in this study, morphine use was associated with
delayed activity of ticagrelor and prasugrel.
Some studies have indicated that the onset of action of
ticagrelor with respect to IPA is slower than previously
suggested [77] and that there are pharmacodynamic dif-
ferences compared with prasugrel [78, 79]. The use of
ticagrelor suspension (crushed tablets) has the potential to
increase the rate of onset of action. In the randomized
MOJITO (Mashed or Just Integral Pill of Ticagrelor) study
in STEMI patients, crushed ticagrelor tablets resulted in an
earlier onset of IPA compared with standard integral tablets
[80]. The randomized LIQUID (Oral Crushed and Dis-
persed Ticagrelor 180 mg Compared to Whole Tablets of
Equal Dose in STEMI Patients Undergoing Primary PCI: A
Pharmacodynamic and Pharmacokinetic Comparison)
Fig. 3 Mean (±standard deviation) final-extent inhibition of platelet
aggregation (IPA) on a day 1 and b day 28 in Japanese patients with
stable coronary artery disease treated with low-dose aspirin plus
ticagrelor 45 mg twice daily (bid), ticagrelor 90 mg bid or clopidogrel
75 mg once daily (qd) [43]. (From: Hiasa et al. [43]. With kind
permission from Springer Science and Business Media)
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study (ClinicalTrials.gov study ID: NCT02046486) is an
extension of the MOJITO study and includes detailed
pharmacokinetic and pharmacodynamic assessments.
3.2.4 Effect of Switching Antiplatelet Agents on Ticagrelor
Pharmacodynamics
RESPOND (Response to Ticagrelor in Clopidogrel Non-
responders and Responders and Effect of Switching Ther-
apies) was a two-way crossover study of 98 patients with
stable CAD [81]. At the study start, all patients received a
single 300 mg clopidogrel dose and ADP-induced platelet
aggregation was assessed prior to dosing and at 6–8 h post-
dose. If the absolute change in platelet aggregation was
B10 %, patients were classified as non-responders. In study
period 1, clopidogrel non-responders and responders were
randomized 1:1 to receive aspirin and ticagrelor (180/
90 mg once daily) or clopidogrel (600/75 mg once daily)
[81]. In study period 2, all non-responders and half of the
current responders switched treatment (i.e. from clopido-
grel to ticagrelor or from ticagrelor to clopidogrel), and the
others remained on their period 1 treatment. The study
reported rapid enhancement of platelet inhibition in
clopidogrel responders as well as non-responders after a
switch to ticagrelor. Absolute IPA increased by 26.4 % in
patients who switched from clopidogrel to ticagrelor
treatment. In contrast, switching to clopidogrel resulted in a
24.5 % reduction in absolute IPA.
Cangrelor, which binds to the same site on the P2Y12
receptor as ticagrelor, is approved in the EU for the
reduction of thrombotic cardiovascular events in adult
patients with CAD undergoing percutaneous coronary
intervention who have not received an oral P2Y12 inhibitor
prior to this procedure and in whom oral therapy with
P2Y12 inhibitors is not feasible or desirable [82]. Because
of its very short half-life, intravenous cangrelor leads to
rapid and extensive IPA with almost full recovery of pla-
telet activity within 60–90 min of withdrawal [83].
Potentially, in some clinical situations, patients may switch
between ticagrelor or clopidogrel to cangrelor and vice
versa. In a study in dogs, various switching regimens of
ticagrelor, clopidogrel and cangrelor were investigated
[84]. The study showed that 2 h after clopidogrel, IPA was
reduced from 69 to 39 % when clopidogrel was given after
cangrelor infusion versus clopidogrel alone. When clopi-
dogrel was dosed 3 h after ticagrelor, IPA was reduced
from 68 to 38 % at 24 h versus clopidogrel alone. An
interaction was not seen when clopidogrel was dosed 7 h
after ticagrelor. No pharmacodynamic interaction occurred
between ticagrelor and cangrelor. The pharmacodynamic
effects of switching from cangrelor to ticagrelor, and from
ticagrelor to cangrelor, were assessed in patients with
stable CAD [85]. Patients received a bolus plus a 2-h
infusion of cangrelor and also 180 mg of oral ticagrelor at
0.5 or 1.25 h. Following this schedule, patients received
ticagrelor (90 mg twice daily) for 6 or 7 days, during
which time pharmacodynamic effects were assessed on day
5 before, and during, a bolus plus 2-h infusion of cangrelor.
Pharmacodynamic assessments included light transmission
aggregometry, a VerifyNow P2Y12 assay and platelet
activation. The study concluded that the pharmacodynamic
effects of cangrelor were not attenuated by ticagrelor. In
addition, the pharmacodynamic effects of ticagrelor were
preserved when ticagrelor was given during infusion of
cangrelor. These data suggest that ticagrelor can be
administered before, during or after cangrelor treatment
without apparent treatment interaction.
Switching from ticagrelor to prasugrel has also been
evaluated in 110 patients with stable CAD [86]. An initial
loading dose of ticagrelor (180 mg) was administered,
followed by a 3- to 5-day run-in phase of ticagrelor 90 mg
twice daily. Patients were then randomized to continue
ticagrelor or to switch to prasugrel 10 mg once daily with
or without a 60 mg prasugrel loading dose. Switching from
ticagrelor to prasugrel was associated with an increase in
platelet reactivity—this effect was partially mitigated when
a 60 mg loading dose of prasugrel was administered.
4 Ticagrelor Pharmacogenetic Profile
Inadequate antiplatelet effects are observed in up to one
third of patients receiving clopidogrel [87–89]. Reasons for
this variation in response may be the presence of poly-
morphisms in genes such as CYP2C19 and ABCB1. In the
pooled analysis of the RESPOND and ONSET/OFFSET
studies [89], CYP2C19 genotype influenced the antiplatelet
activity of clopidogrel, whereas the antiplatelet activity of
ticagrelor was not associated with CYP2C19 genotype.
Ticagrelor exhibited lower platelet reactivity (i.e. less
platelet aggregation) than clopidogrel for all assays used in
the study irrespective of CYP2C19 genotype. The ABCB1
genotype did not significantly influence platelet response in
either the ticagrelor or clopidogrel treatment groups.
A large genetic substudy was performed as part of the
PLATO trial [90]. This substudy showed that CYP2C19
and ABCB1 polymorphisms were independent of the lower
rates of cardiovascular death, MI or stroke observed in
patients treated with ticagrelor compared with clopidogrel.
Rates of total major bleeding were similar between the
ticagrelor and clopidogrel groups in this substudy. A gen-
ome-wide association study (GWAS) of patients from the
PLATO study identified single nucleotide polymorphisms
(SNPs) affecting cystatin-C levels [91]. However, the
composite clinical outcome of first occurrence of MI or
cardiovascular death within the first year was not
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associated with cystatin-C genotype. A further GWAS
study in the PLATO trial showed that plasma levels of
ticagrelor and AR-C124910XX were associated with a
SNP in the solute carrier organic anion transporter family
member 1B1 (SLCO1B1) gene [92]. This SNP is in linkage
disequilibrium with a functional variant that leads to
decreased organic anion transporting polypeptide 1B1
(OATP1B1) activity. In the same study, plasma ticagrelor
levels were associated with two independent SNPs in the
CYP3A4 region, and AR-C124910XX levels were associ-
ated with a SNP in the UDP-glucuronosyltransferase 2B7
(UGT2B7) gene. However, the effects on plasma ticagrelor
and AR-C124910XX at each of these loci were small, and
none were associated with clinical outcomes.
5 Conclusions
The pharmacokinetic and pharmacodynamic profiles of
ticagrelor are unique. Unlike other currently available
antiplatelet agents, ticagrelor does not require metabolic
activation and it binds rapidly and reversibly to the P2Y12
receptor. Patients with ACS represent broad populations
who often have comorbidities and are likely to be taking
several different classes of drug. Exposure to antiplatelet
agents as measured by pharmacokinetic studies may vary
in different populations. Understanding the pharmacologi-
cal profile of oral antiplatelet agents is important to avoid
drug–drug interactions and to provide optimal dosing. This
review has summarized what is currently known about the
pharmacokinetic, pharmacodynamic and pharmacoge-
nomic profiles of ticagrelor.
Studies in healthy volunteers showed that dose adjust-
ments for ticagrelor were not required on the basis of age,
gender or ethnicity. Severe renal impairment and mild
hepatic impairment also do not necessitate dose adjust-
ments. Pharmacokinetic data are not currently available in
patients with moderate and severe hepatic impairment or
those on renal dialysis, and use of ticagrelor in patients
with severe hepatic impairment is contraindicated. Expo-
sure to ticagrelor is higher in Japanese and Chinese pop-
ulations versus Caucasians; however, these differences are
not considered to be clinically relevant and dose adjust-
ments are not required. African-American and Hispanic
populations show a ticagrelor pharmacokinetic/pharmaco-
dynamic profile similar to that of Caucasians. The clinical
relevance of the increased plasma concentrations of tica-
grelor observed at 0.5 and 1 h with use of crushed tablets
has yet to be shown. Drug interaction studies show that
ticagrelor should not be co-administered with strong
CYP3A inhibitors or inducers, and use with statins at doses
greater than 40 mg should be avoided. Patients receiving
P-gp-dependent drugs with a narrow therapeutic range, at
the same time as ticagrelor, should be monitored appro-
priately. Current data show that proton pump inhibitors
(metabolized by CYP2C enzymes) are unlikely to have any
significant pharmacokinetic interaction with ticagrelor.
The non-P2Y12 receptor actions of ticagrelor warrant
further investigation, in particular the possible beneficial
effects on cardiac perfusion. Current data suggest that, if
necessary, patients who are not responsive to clopidogrel
can be switched directly to ticagrelor with an increase in
IPA. In contrast, switching from ticagrelor to clopidogrel is
associated with a reduction in IPA. Genetic variations
appear to influence response to clopidogrel. However, there
is currently no evidence to show that this is true for
ticagrelor.
Ongoing studies will provide additional insights into the
pharmacology of ticagrelor and will help support individ-
ualized P2Y12 inhibitor treatment, in line with guideline
recommendations.
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